In this study, we found that the active ingredients of HLJDD including quercetin, kaempferol, berberine, acetic acid, and wogonin may act on multiple targets such as TNF, IL-6, IL-8, PTGS2, and IL-10 and regulate multiple signalling pathways such as the AGE-RAGE, NF-κB, HIF-1, IL-17, and PPAR signalling pathways to regulate lipid localization and storage, reactive oxygen species metabolic processes, and inflammatory responses, thereby achieving the treatment of dyslipidemia. The gene discussed is PPARA; the disease is metabolic syndrome.